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Abstract
Background: Autosomal dominant polycystic kidney disease (ADPKD) is the most common potentially life threatening
inherited kidney disease and is responsible for 5–10% of cases of end-stage kidney disease (ESKD). Cystic kidneys may
enlarge up to 20 times the weight of a normal kidney due to the growth of renal cysts, and patients with ADPKD have
an increased risk of morbidity, premature mortality, and other life-time complications including renal and hepatic cyst
and urinary tract infection, intracranial aneurysm, diverticulosis, and kidney pain which impair quality of life. Despite
some therapeutic advances and the growing number of clinical trials in ADPKD, the outcomes that are relevant to
patients and clinicians, such as symptoms and quality of life, are infrequently and inconsistently reported. This
potentially limits the contribution of trials to inform evidence-based decision-making. The Standardised Outcomes in
Nephrology—Polycystic Kidney Disease (SONG-PKD) project aims to establish a consensus-based set of core outcomes
for trials in PKD (with an initial focus on ADPKD but inclusive of all stages) that patients and health professionals
identify as critically important.
Methods: The five phases of SONG-PKD are: a systematic review to identify outcomes that have been reported in
existing PKD trials; focus groups with nominal group technique with patients and caregivers to identify, rank, and
describe reasons for their choices; qualitative stakeholder interviews with health professionals to elicit individual values
and perspectives on outcomes for trials involving patients with PKD; an international three-round Delphi survey with all
stakeholder groups (including patients, caregivers, healthcare providers, policy makers, researchers, and industry) to
gain consensus on critically important core outcome domains; and a consensus workshop to review and establish a set
of core outcome domains and measures for trials in PKD.
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Discussion: The SONG-PKD core outcome set is aimed at improving the consistency and completeness of outcome
reporting across ADPKD trials, leading to improvements in the reliability and relevance of trial-based evidence to
inform decisions about treatment and ultimately improve the care and outcomes for people with ADPKD.
Keywords: Core outcome set, Outcomes research, Patient-centred outcomes clinical trials, Chronic kidney disease,
Autosomal dominant polycystic kidney disease
Background
Autosomal dominant polycystic kidney disease (ADPKD)
is the most common inherited kidney disorder and is
responsible for 5–10% of end-stage kidney disease
(ESKD) requiring renal replacement therapy [1–3].
ADPKD is life-threatening and irreversible, and affects
an estimated 12.5 million people worldwide [4] occur-
ring equally in men and women, without ethnic dispar-
ities [5, 6]. Gene defects which lead to the development
of ADPKD cause disruption in renal tubular epithelial
differentiation leading to the formation of multiple cysts,
and their expansion due to ongoing cellular proliferation
and fluid secretion [7, 8]. The cysts progressively grow,
enlarging kidneys up to 20 times bigger than normal size
[9], displacing and destroying normal kidney tissue
culminating in fibrosis and ultimately kidney failure [7, 8].
The rate of decline in kidney function is highly variable
amongst patients (i.e. annual rate of decline in creatinine
clearance 1.71 to 5.8 mL/min/1.73 m2), with greater
reported rate of reduction in those who progress to ESKD
[10, 11]. Up to 70% of patients with ADPKD progress to
ESKD by the age of 65 years [12], and the annual cost of
renal replacement therapy (RRT) provision for ADPKD
patients in Europe alone approximates to 1.5 billion Euros
[13]. Patients with ADPKD are also at high risk of compli-
cations including debilitating kidney pain, hepatic cysts,
infection, intracranial aneurysms, and cardiovascular dis-
ease that may severely impair quality of life and well-being.
The past decade has witnessed some therapeutic
advances, with treatments targeting proliferation of cysts
[14] and cyst growth [15]. Despite the growing number
of trials in ADPKD, the outcomes that are relevant to
patients and clinicians, such as symptoms and quality of
life, are infrequently and inconsistently reported [16].
Typically, patients are not included in the selection of
outcomes and this may cause a mismatch in priorities
between patients and clinicians [17]. For example,
patients with ADPKD identified the psychosocial impact
of diagnosis and the progression to ESKD as important
outcomes, but these were not identified by health pro-
fessionals on the guideline working group [17]. Pain,
financial impact, stress, and anxiety are important con-
cerns amongst patients but are inconsistently reported
in trials. Although selected larger sized trials have
reported quality of life-related outcomes, such as pain
[15, 18], most trials have focused their attention on
reporting biochemical and imaging parameters such as
kidney function (e.g. estimated glomerular filtration rate
(eGFR), serum creatinine concentration, doubling of
serum creatinine or novel biomarkers) [14, 19–22] and
kidney structure (e.g. kidney and cyst volumes) [14, 21,
22]. There are new initiatives currently being developed
to improve research quality (e.g. PKD Outcomes Con-
sortium, https://c-path.org/programs/pkd/) and tools to
better capture ADPKD-specific health-related outcomes
(e.g. ADPKD-Impact Scale) [23].
Other problems with outcome reporting include vari-
ability in the outcomes measured and reported among
trials, and the potential outcome reporting bias. The
heterogeneity of outcomes can jeopardise the ability to
compare and combine trial results and reliably estimate
relative effectiveness [24]. In a systematic review on the
prevention of progression of chronic kidney disease
(CKD) in patients with ADPKD, changes in kidney func-
tion were reported using serum creatinine (12 trials),
GFR (13 trials), doubling of creatinine (4 trials), or need
for RRT (2 trials) [16]. Only one or two studies were
able to be included in each meta-analysis per outcome
because of variability in the definitions adopted [16].
Without a core outcomes set routinely reported in all
trials, selective reporting of outcomes found to favour
the intervention may occur, leading to an overestimation
of the true effect of the intervention, or failure to report
adverse events which can expose patients to unrecog-
nised risks of harm [25–27].
The increasing recognition of inefficiency and waste in
medical research, attributed to problems with outcome
selection [28], has given rise to numerous initiatives
across medical specialties worldwide to develop core
outcome sets—defined as an agreed minimum set of
standardised outcomes that should be measured and
reported in all trials on a specific clinical topic [29, 30].
This does not preclude trialists adding other outcomes
specific to the trial population and intervention. The
first of these initiatives was the Outcome Measures in
Rheumatology (OMERACT), which was formed in 1992
to identify core outcomes in rheumatology through a
consensus process involving healthcare providers, policy
makers, patients, and their caregivers [31–33]. The
implementation of OMERACT core outcomes has
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improved the reporting and relevance of outcomes in
rheumatology trials [33–35]. More recently, the Core
Outcome Measures in Effectiveness Trials (COMET) ini-
tiative was formed in 2010 to facilitate the development
and implementation of core outcome sets [36, 37].
In nephrology, the Standardized Outcomes in Neph-
rology (SONG; www.songinitiative.org) initiative was
formed in 2015 to establish core outcomes across the
full spectrum of CKD. Ongoing work is focussed on
haemodialysis (SONG-HD) [38–40], kidney transplant-
ation (SONG-Tx) [41], peritoneal dialysis (SONG-PD),
and paediatric CKD (SONG-Kids) [42]. The SONG-
Polycystic Kidney Disease (SONG-PKD) project aims to
establish a core outcome set for trials and other types of
clinical research involving patients with ADPKD. The
initial focus of SONG-PKD will be on ADPKD as it is
the most common form of PKD and presents differently
to autosomal recessive polycystic kidney disease
(ARPKD). The SONG-PKD Steering Group was con-
vened in June 2017 and is comprised of a multidisciplin-
ary team of health professionals and patients with PKD.
The aims of SONG-PKD are to: describe the scope and
consistency of outcomes reported in trials in ADPKD;
identify and prioritise outcomes that are important to
patients with ADPKD and their caregivers (including the
reasons for their choices); generate insights on health
professionals’ perspectives on outcomes in ADPKD; de-
velop a consensus-based set of core outcomes of critical
importance to all stakeholder groups including patients/
caregivers and health professionals; and establish a set of
core outcome domains to be reported in all trials in
patients with ADPKD.
Methods/design
The SONG-PKD project will follow the SONG method-
ology [43], which has been adapted from the OMER-
ACT and COMET initiatives [31, 36]. The five phases
will include: a systematic review, focus groups with
nominal group technique, semi-structured interviews
with stakeholders, an international Delphi survey, and a
consensus workshop (Fig. 1).
Phase 1: Systematic review of outcome domains reported
in PKD trials
We will conduct a systematic review to identify and
assess the scope and consistency of outcome domains and
outcome measures reported in randomised controlled
trials (RCTs) of interventions for adults with ADPKD.
Study search strategy
A comprehensive search of MEDLINE, Embase, the
Cochrane Kidney and Transplant Specialized Register,
Australian and New Zealand Clinical Trials Registry
(ANZCTR; www.anzctr.org.au), EU clinical trials register
(www.clinicaltrialsregister.eu) and ClinicalTrials.gov will
be conducted to identify all RCTs that enrolled patients
with ADPKD aged 18 years or older. We will not apply
date or language restrictions.
All RCTs published in peer-reviewed journals and trial
protocols registered in ClinicalTrials.gov, ANZCTR, and
EU clinical trials register will be included (up to 2 March
2017). Abstracts and conference reports will not be
included as they do not provide a complete and reliable
source of all the outcomes reported and measured in trials.
Types of interventions
Any intervention used to treat and manage adult
patients with ADPKD will be included. These may
include pharmacological, surgical, lifestyle, psychosocial,
and health service interventions.
Types of participants
Adult patients with ADPKD aged 18 years or older will
be eligible. Studies that exclude patients with ADPKD,
Fig. 1 SONG-PKD study flowchart. PKD polycystic kidney disease
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or only enrol children (aged 18 years or below) with
ADPKD will not be included. Given the focus on
ADPKD, trials in which patients with ADPKD comprise
less than half the study population across all arms will
be excluded.
Eligibility of studies
All records retrieved from the electronic searches will be
independently assessed by two reviewers (BS and YC).
The full texts of all potentially relevant RCTs will be
independently assessed by the two reviewers (BS and YC).
Any disagreement on the eligibility of studies will be
resolved through discussion with a third reviewer (AT).
Data extraction
Characteristics from all included trials will be extracted
by one reviewer (BS) and will include the following: first
author, publication date, country in which the trial was
conducted, participant characteristics (age, sex), trial
duration, name and type of intervention (e.g. pharmaco-
logical, psychosocial, lifestyle), and primary or secondary
outcomes as reported in the trial (including definitions,
measurement instruments, thresholds, measurement
time points or time frames, changes in level or percentage,
scores) [37–44]. Outcomes reported in the registration for
each trial published will be evaluated in order to assess
the selective reporting of outcomes. Two reviewers will
cross check the data extraction (BS and YC).
Data analysis and presentation
The reviewer (BS) will group similar outcomes into out-
come domains which will be classified as surrogate,
clinical, or patient-reported. A surrogate endpoint or
outcome is a biochemical or imaging marker used to
substitute for a clinical outcome (e.g. total kidney vol-
ume) [45–47]. A clinical outcome is a medical outcome
that is determined or diagnosed by the clinician (e.g. in-
fection) [40, 48, 49]. Patient-reported outcomes are re-
ported directly from patients regarding how they
function or feel in relation to a health condition and its
therapy, without interpretation by a healthcare profes-
sional or anyone else (e.g. pain). The domains will be
reviewed and discussed by the SONG-PKD Steering
Group. The frequency of reporting across trials for each
outcome domain will be ascertained. The primary
outcome, if specified, will be identified and analysed.
The number of different outcomes (including outcome
measures and measurement time points) and the num-
ber of trials that assessed each specific outcome will
also be assessed. Statistical analyses will be performed
using R version 3.2.3 (R Foundation for Statistical Com-
puting, Vienna, Austria).
Phase 2: Nominal group techniques with patients and
caregivers
Patients with ADPKD and their caregivers (including
family members) will identify and rank outcomes that
they consider are important to include in trials and will
discuss reasons for their choices. The nominal group
technique is highly recommended as a transparent,
equitable, and systematic approach [50–52] to generate
ideas and consensus on priorities in health, including
outcomes in CKD [53, 54], and allows each participant
to raise their views and suggestions without direct rejec-
tion or criticism from others in the group [52].
Participants and recruitment
Patients with ADPKD aged 18 years and older and their
caregivers will be eligible to participate. We will aim to con-
vene a minimum of 20 nominal groups (involving 8–12
participants per session, estimated total n = 200). The final
number of groups will depend on when data saturation,
defined as the point when few or no new outcomes or
issues are emerging, is reached [54–56].
Participants will be recruited initially from participat-
ing centres across Australia (Westmead Hospital,
Princess Alexandra Hospital, Monash Medical Centre),
and will aim to recruit sites in other countries upon
funding securement.
We will use a purposive sampling strategy to achieve
maximum diversity in demographics (age, sex, socioeco-
nomic status, ethnicity, location, and educational
attainment) and clinical characteristics (stages of chronic
kidney disease; i.e. patients not on RRT, CKD stage 1–5;
patients on haemodialysis or peritoneal dialysis, CKD
stage 5D; and patients with a kidney transplant, CKD
stage 5 T; time since diagnosis, comorbidities, and
complications). Informed consent will be obtained from
all participants. Each participant will be reimbursed in
cash (A$50) to help support their transport to attend
the session.
Data collection
Each focus/nominal group will be 2 h in duration and
take place in a centrally located venue external to the
hospital in order to encourage open discussion and to
minimise censoring of conversation among participants
due to feeling disempowered in a clinical setting. The
question guide will be developed based on those previ-
ously used to elicit patient-prioritised outcomes in
kidney transplantation and haemodialysis [53, 54], and
with input from the SONG-PKD Steering Group and
investigators. Each group will cover the following:
Welcome and introduction (10 min): The facilitator
will explain the aims of the study, define what outcomes
are in the context of clinical trials, and ask participants
to introduce themselves.
Cho et al. Trials  (2017) 18:560 Page 4 of 11
Focus group discussion (40 min): Participants will be
asked to discuss their experiences of living with ADPKD,
including perceived benefits, harms, and complications
related to the disease and treatment.
Nominal group technique (70 min): Each participant
will be asked to suggest one or two outcomes they
consider are the most important to be reported in trials
in ADPKD. The facilitator (YC, BS, AT, TG) will write
all suggested outcomes on the flipchart/board and ask
the group to provide clarification as required or to
discuss their reasons for their suggestion. Once the
group has generated the outcomes, the facilitator will
add to the flipchart/board outcomes identified from the
systematic review (Phase 1) and in previous nominal
groups. The list of outcomes will be discussed to ensure
that all members understand the meaning of each out-
come. A copy of the outcomes will be printed for partic-
ipants to individually rank all the outcomes in the order
of perceived importance, from 1 (most important) to X
(least important). The facilitator will ask participants to
read out their top three and note these on the flipchart/
board. Similarities and differences in ranking will be
discussed among the group.
All discussions during the session will be audiotaped
and transcribed verbatim, and a note-taker will record
the contextual details around the discussion.
Data analysis
Quantitative analysis A measure of importance (i.e.
importance score) of each outcome, based on the
rankings attributed in the focus/nominal groups, will be
used to prioritise the outcomes. The calculation of this
measure is described as follows.
The distribution of the ranking for each outcome is
obtained by calculating the probability of each rank for
each outcome. Using mathematical notation, this is
written as P(Oj in rank i), i.e. the probability of the
outcome Oj being assigned the rank i. Thus, for each
outcome we obtain the probability of being ranked in first
place, in second place, and so on. By the total law of prob-
abilities, these probabilities can be decomposed as:
P Oj in rank i
  ¼
¼ P Oj in rank i Oj is nominated
 
 P Oj is nominated
 
þ P Oj in rank i Oj not nominated
 
 P Oj not nominated
 
where “nominated” means that the outcome was consid-
ered (and given a rank) by the participant. We will
assume that the P(Oj in rank i |Oj not nominated) is 0.
The reasoning for this is that if the participant did not
mention the outcome Oj, then the probability of any
rank is 0. Therefore, the expression above simplifies to
P Oj in rank i
  ¼ P Oj in rank i Oj is nominated
 
 P Oj is nominated
 
From this expression, we can observe that the prob-
ability has two components: 1) the importance given to
the outcome by the ranking; and 2) the consistency of
being nominated by the participants. We then use these
probabilities and compute the weighted sum of the
inverted ranking 1i
 
to obtain the importance score (IS)
IS ¼
X
i¼1
nr of
outcomes
P Oj in rank i
   1
i
The importance score can be interpreted as a summary
measure of importance of the outcome that incorporates
the consistency of being nominated and the rankings
given by the participants. The reason for inverting the
ranks is to give more weight to top ranks and less to lower
ranks. Higher values of the score identify outcomes that
are more valued by the participants. The standard errors
for the importance score can be obtained through boot-
strapping. This measure has a similar motivation to the
Expected Reciprocal Rank Evaluation Metric that was
proposed in a different context [57].
The importance scores will also be calculated separately
for patients and their caregivers/family, and these results
will be compared using a t test with a statistical signifi-
cance level of p < 0.05. The analysis will be conducted
using the software package Stata/SE version 14.0
(StataCorp., College Station, TX) and the R version 3.2.3
(R Foundation for Statistical Computing, Vienna, Austria).
Qualitative analysis The transcripts will be imported into
HyperRESEARCH (ResearchWare Inc., www.researchwar-
e.com, version 3.7.2) software to facilitate qualitative data
analysis. The transcripts will be reviewed line by line to
identify concepts, and similar concepts will be grouped into
themes that reflect the reasons for identifying and ranking
the outcomes. The preliminary findings will be discussed
among the research team to ensure that themes reflect the
full breadth and depth of the data.
Phase 3: Stakeholder interviews
Semi-structured interviews will be conducted with
health professionals to capture the range and depth of
individual values, beliefs, and attitudes towards out-
comes in PKD [56, 58]. We will use the Consolidated
Criteria for Reporting Qualitative Health Research
(COREQ) [59] to report this study.
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Participants and recruitment
Health professionals (nephrologists, hepatologists, surgeons
(i.e. urologists, transplant surgeons), geneticists, nurses, and
allied health professionals (i.e. psychologists, social workers,
genetic counsellors, dietitians)) who have expertise, experi-
ence, and interest in ADPKD will be eligible to participate
in an interview. A minimum of 50 participants will be
recruited worldwide through the networks of the Steering
Group and investigators. We will apply a purposive
sampling strategy to ensure a broad spectrum of perspec-
tives by maximising variability in demographics, profes-
sional role, and experience. We will also specifically identify
key informants who have experience in research (trials) and
roles in policy making. Recruitment will continue until data
saturation has been achieved. All participants will provide
informed consent prior to the interview [55, 56, 60].
Data collection
Results from the systematic review (Phase 1) and nom-
inal group techniques (Phase 2) will inform the design of
the interview guide. We will conduct face-to-face inter-
views unless video-conferencing or telephone interviews
are preferred by the participants, or when an in-person
interview cannot be feasibly organised. Participants will
be asked to reflect and discuss their perspectives on: 1)
their role and experiences in providing care for patients
with ADPKD, 2) aspects of treatment or care that are
challenging, 3) shared-decision making in the context of
ADPKD, 4) outcomes they consider to be critical or rele-
vant to include in PKD trials and their reasons, 5) the
results obtained from the nominal group technique
study (Phase 2), and 6) views on the development and
implementation of core outcomes in PKD trials. Each
interview will take approximately 40 min, and will be
audio-recorded and transcribed.
Data analysis
We will extract a list of outcomes suggested by the
participants. Thematic analysis as described in Phase 2
of the project will be used to identify themes that reflect
the attitudes, beliefs, and perspectives of the partici-
pants. Four investigators (YC, BS, TG, and AT) will be
involved in the data analysis and review preliminary
findings to ensure that the coding framework captures
the full range and depth of the data collected. The pre-
liminary findings will also be sent to all participants (i.e.
member checking) for feedback and comment, and to
add relevant perspectives as needed. This can enhance
the analytical framework and ensure that the results
reflect the perspectives of the participants.
Phase 4: International online Delphi consensus survey
We will conduct an international online Delphi survey
to gain consensus on the outcome domains that are
critically important to all stakeholder groups for trials in
ADPKD. The Delphi survey has been successfully used
to reach consensus on core outcome sets for various
health conditions or treatments [61–64], including in
haemodialysis and kidney transplantation [65, 66]. The
Delphi technique usually involves three rounds of
surveys completed sequentially and anonymously by a
panel of experts with experience or expertise on the
topic of interest [30, 51]. Respondents contribute their
individual perspectives (for example, rating the import-
ance of an outcome) and, in subsequent rounds, partici-
pants can view their previous scores and the results of
the group, reflect on the group results, and have the
option of revising their opinion. This process results in
equitable contribution from all participants as it allows
individual respondents to express independent thought
and minimises direct confrontation. Previous SONG
Delphi surveys have demonstrated that participants do
not appear to be unduly influenced by the group results
(for example, increases in scores occur in both the
patient/caregiver and health professional groups), and
the scores of both stakeholder groups converge over the
three rounds.
Participants and recruitment
The majority of Delphi studies used to develop core out-
comes across medical specialties have reported sample
sizes ranging from 13 to 222 participants. Over 1000
participants from more than 70 countries have partici-
pated on the Delphi panel for the studies conducted as
part of the SONG-HD and SONG-Tx project [65, 66].
For the SONG-PKD Delphi panel, we will aim to recruit
a minimum sample size of 1000 respondents where pa-
tients/caregivers comprise at least 50% of the sample
size. Specifically, we will aim to recruit patients/care-
givers (n = 500), clinicians (nephrologists/surgeons (i.e.
urologists, transplant surgeons)/geneticists (n = 400)),
nurses and allied health professionals (psychologists,
genetic counsellors, and dietitians (n = 60)), researchers
(n = 20), industry (n = 20), and policy makers (n = 20).
We will use multiple sampling strategies to be as
broadly inclusive as possible. Participants will be identi-
fied by using a purposive strategy similar to those
detailed in Phase 3 to ensure broad representation of
views and snowballing whereby participants can nomin-
ate other eligible individuals to participate. Participants
will be recruited globally through participating university
institutions/hospitals of the SONG-PKD Steering Group
and investigators, the SONG Initiative database, and
patient/consumer organisations. All participants will be
required to register their name and email address via
www.songinititative.org to receive a standard study
information sheet. Informed consent will be obtained
from all participants.
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Data collection
The Delphi survey will include approximately 30 outcome
domains identified from Phases 1–3 of SONG-PKD. Each
outcome will include a definition written in plain
language. The draft Delphi survey will be reviewed by the
SONG-PKD Steering Group and pilot tested with at least
10 patients/caregivers. The survey will be custom
programmed and administered online using Qualtrics. All
participants will be assigned a unique identifier based on
their name and email address to link their responses
across all three rounds of the Delphi survey. At least two
reminders will be sent to participants per round. We aim
to retain at least a 70% response rate across all rounds.
Round 1 Participants will rate the importance of each
outcome domain using the GRADE nine-point Likert
scale [67]. Ratings of 1–3 indicate outcomes of limited
importance, ratings of 4–6 indicate outcomes of import-
ance but not critical, and ratings of 7–9 indicate
outcomes of critical importance. An option “unable to
score” will also be available. In order to minimise the
risk of ordering bias, the outcomes domains will be
randomised. For each outcome, a text box is provided
for participants to provide comments about their
choices. After the rating scales are completed, partici-
pants can suggest new outcomes. All outcome domains
that are suggested by more than 10% of the participants,
and do not duplicate outcomes in the original survey,
will be included in Round 2.
We will review the distribution of scores across all out-
comes for each stakeholder group, i.e. patients/caregivers
and health professionals. Any outcomes with a median
and mean of more than 7 will be retained for Round 2.
Any new outcomes suggested by more than 10% of the
participants will also be included in the next round. This
is based on criteria established for previous SONG Delphi
surveys [38, 66]. Any outcomes excluded in subsequent
rounds will be listed as “outer tier” outcomes, i.e. import-
ant to some or all stakeholder groups to consider for trials;
or “middle tier” outcomes, i.e. critically important to some
stakeholder groups to report in some trials (Fig. 2).
Round 2 The participants will be shown their previous
score for each outcome (highlighted in the rating scale),
and will be presented with a column graph of the distri-
bution of scores for all participants (equally weighted by
stakeholder group), patients/caregivers, and health pro-
fessionals. A plain language explanation and an example
will be provided to help participants understand how to
interpret the graph. Participants will also see comments
from patients/caregivers and health professionals in
separate scroll down boxes. Participants will be asked to
re-rate the outcomes on the same GRADE 9-point
Likert scale. A text box will be provided for optional
comments such as reasons for their ratings.
An outcome with a median and mean of more than 7,
and with 70% or more participants in both stakeholder
groups (i.e. patient/family member and health profes-
sionals) rating the outcome to be of critical importance
(7–9), will be included in Round 3.
Round 3 In this final round of survey, participants will
see their previous score highlighted and again review the
distribution of scores for all participants, patients/care-
givers, and health professionals, and comments from
Round 2. They will be asked to re-rate the importance
of each outcome, and have the opportunity to provide
additional comments in a free-text box. To assess the
relative importance of the outcomes, we will include a
Best–Worst Scale survey [68]. Participants will be
presented with approximately six blocks of six outcome
domains in which they select the most important and
the least important outcome from the list.
Data analysis
For all three rounds, we will show the distribution of
scores and calculate the mean, median, and proportion
of participants rating the outcome of critical importance.
For the Best–Worst Scale Survey, multinomial logistic
regression models will be used to calculate the relative
importance score for each outcome domain normalised
to the range of 1 (least important) to 9 (most important).
Fig. 2 SONG conceptual schema of core outcomes
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This will be calculated separately for patients/caregivers
and health professionals.
For feasibility, three to five outcome domains are
included in the core set and all other outcomes are clas-
sified as middle and outer tier outcomes (Fig. 2). It is
possible that more than five outcomes may be identified
based on the SONG pre-specified definition of consen-
sus. For outcomes to be included in the core set, the
outcome must have: a median score of greater than or
equal to 8; a mean score greater than or equal to 7.5; the
proportion of participants rating the outcome as ‘critic-
ally important’ being greater than or equal to 75%, and a
median score of less than 10 in the forced ranking
question [65, 66]. As we are unable to determine the
distribution of scores, the thresholds for inclusion of
an outcome domain as a core outcome may need to
be determined post-hoc and discussed at the consen-
sus workshop (Phase 5). Several subgroup analyses
will be conducted according to country, gender, CKD
stage, and primary role (e.g. patient/caregiver, health
professionals).
Phase 5: Consensus workshop
A face-to-face stakeholder consensus workshop will be
convened to obtain feedback and discuss the proposed core
outcomes for trials in PKD as identified from Phases 1–4.
The meeting will be chaired and facilitated by members of
the SONG-PKD Steering Group, and held in conjunction
with an international nephrology conference to maximise
participation. Based on previous consensus workshops,
and to ensure feasibility and group manageability [40, 69],
we will invite approximately 60 participants, including at
least 20 patients with ADPKD and their caregivers. Health
professionals (nephrologists, surgeons, geneticists, nursing,
allied health professionals, researchers, policy makers, and
industry) with a range of clinical and research experience
in ADPKD, including in clinical trials, or who have leader-
ship or advisory roles in major research, funding, and regu-
latory agencies will be invited to attend. Patients and
caregivers attending the workshop will be reimbursed for
transportation and parking.
A copy of results from Phases 1–4 will be provided to
participants approximately 2 weeks before the workshop
so that participants can have the opportunity to ask
questions or seek clarification by email, and understand
the SONG-PKD process and results to inform the
discussion. The workshop will comprise of three sessions.
Session 1: Introduction
We will present an introduction to the SONG-PKD
initiative, including the process and results from the
Phases 1–4, and the proposed set of core outcome
domains with the threshold and rationale for inclusion.
Session 2: Breakout group discussion
Participants will be allocated to six breakout groups with
up to 12 participants in each group (including a facilita-
tor and co-facilitator). Each group will include at least
three patients/family members/caregivers to encourage
exchange of different perspectives and opinions, and
breadth of discussion. All facilitators will attend a brief-
ing session and be provided with a question guide prior
to the session commencement. Participants will be asked
to reflect on and discuss their opinions on the proposed
core outcome domains.
Session 3: Plenary discussion
The Chair of the workshop will moderate a plenary
discussion. A nominated spokesperson from each break-
out group will present a summary of the discussion to
the wider group who will have the opportunity to
respond and discuss the issues raised by other groups.
The Chair will summarise the key points raised across
all breakout groups.
All breakout and plenary discussion will be audiotaped
and transcribed verbatim. An investigator (YC) will sum-
marise the discussion with input from other investiga-
tors (BS, AT, and TG) to ensure that the summary is
comprehensive and captures all the points raised in the
discussion. A draft plain language report will be circu-
lated to the workshop attendees and collaborators for
feedback within a 2-week timeframe. The readability of
the plain language report will be at the sixth-grade level,
which will be of lower literacy level than the eight-grade
level as recommended by the Centers for Disease
Control and Prevention (CDC) [70]. Additional
comments will be integrated into the final report.
Establishing the SONG-PKD core outcome domains
The SONG-PKD proposed core outcomes will be
uploaded on the website for 3 weeks for public comment.
The link will also be sent to the SONG Initiative database
and collaborating organisations. All feedback received will
be reviewed by the SONG-PKD Steering Group to finalise
the SONG-PKD set of core outcome domains.
Ethics
This study has been approved by the Human Research
Ethics Committee of The University of Sydney (2015-228),
Westmead Hospital (2009/6/4.14), Monash Medical
Centre (2010.0.31), and Princess Alexandra Hospital
(HREC/17/QPAH/112).
Discussion
The SONG-PKD project engages patients/caregivers and
health professionals in a systematic, transparent, and
equitable consensus process to establish a set of critically
important core outcome domains to be reported in all
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trials involving patients with ADPKD. We will establish
validated, feasible, and robust core outcome measures
for each core outcome domain identified through
SONG-PKD.
Reporting outcomes that are critically important to all
stakeholder groups, particularly patients, will improve
the quality and relevance of research evidence to inform
treatment decisions. We will actively disseminate the
core outcome domains through publications, online
media, and collaborating patient, research, professional,
and policy organisations, and develop targeted strategies
to ensure implementation of the core outcome domains
in trials. Standardised reporting of patient-important
outcomes in clinical trials is expected to translate to
improved patient care and outcomes in ADPKD.
Study status
Recruitment and data collection have commenced.
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